|
136 |
Cardiovascular risk factors and determinants of clinical outcomes in type 2 diabetic patients at a tertiary-care centre |
Maria Jose, Aparna Manjunath, Ganapathy Bantwal, *Denis Xavier* |
International Journal Basic Clin Pharmacol |
2016 |
|
137 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease |
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, et al. |
N Engl J Med |
2016 |
|
138 |
Prevalence of Pragmatically Defined High CV Risk and its Correlates in LMIC: A Report From 10 LMIC Areas in Africa, Asia, and South America |
Carrillo-Larco RM, Miranda JJ, Li X, Cui C, Xu X, Ali M, Alam DS, Gaziano TA, Gupta R, Irazola V, Levitt NS, Prabhakaran D, Rubinstein A, Steyn K, Tandon N, Xavier D, Wu Y, Yan LL |
Glob Heart |
2016 |
|
139 |
Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial |
Xavier D, Gupta R, Kamath D, Sigamani A, Devereaux PJ, George N, Joshi R, Pogue J, Pais P, Yusuf S |
Lancet Diabetes Endocrinol |
2016 |
|
140 |
Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases |
Irazola VE, Gutierrez L, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gaziano T, Levitt NS, Miranda JJ, Ortiz AB, Steyn K, Wu Y, Xavier D, Yan LL, He J, Rubinstein A |
Glob Heart |
2016 |
|
141 |
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease |
Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, et al. |
N Engl J Med |
2016 |
|
142 |
Training and Capacity Building in LMIC for Research in Heart and Lung Diseases: The NHLBI-UnitedHealth Global Health Centers of Excellence Program |
Bloomfield GS, Xavier D, Belis D, Alam D, Davis P, Dorairaj P, Ghannem H, Gilman RH, Kamath D, et al. |
Glob Heart |
2016 |
|
143 |
A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale |
Rao MP, Ciobanu AO, Lopes RD, Fox KA, Xian Y, Pokorney SD, Al-Khalidi HR, Jiang J, Kamath DY, Berwanger O, Xavier D, Bahit CM, Tajer C, Vinereanu D, Huo Y, Granger CB |
Am Heart J |
2016 |
|
144 |
Comparison of Nonblood-Based and Blood-Based Total CV Risk Scores in Global Populations |
Gaziano TA, Abrahams-Gessel S, Alam S, Alam D, Ali M, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gutierrez L, Irazola V, Levitt NS, Miranda JJ, Bernabe-Ortiz A, Pandya A, Rubinstein A, Steyn K, Xavier D, Yan LL |
Glob Heart |
2016 |
|
145 |
Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. |
O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, Rao-Melacini P, Zhang X, Pais P, et al. |
Lancet |
2016 |
|
146 |
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial |
Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW |
BMJ |
2016 |
|
147 |
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study |
Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, Commerford P, Jansky P, Avezum A, Sigamani A, Demasceno A, Reilly P, Grinvalds A, Nakamya J, Aje A, Almahmeed W, Moriarty A, Wallentin L, Yusuf S, Connolly SJ |
Lancet |
2016 |
|
148 |
Age-specific and sex-specific adult mortality risk in India in 2014: analysis of 0·27 million nationally surveyed deaths and demographic estimates from 597 districts |
Ram U, Jha P, Gerland P, Hum RJ, Rodriguez P, Suraweera W, Kumar K, Kumar R, Dikshit R, Xavier D, Gupta R, Gupta PC, Ram F |
Lancet Glob Health |
2015 |
|
149 |
High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective |
Kamath DY, Xavier D, Sigamani A, Pais P |
Indian J Med Res |
2015 |
|
150 |
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial |
Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, Thomas L, Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L |
Am Heart J |
2015 |